Microsoft word - marketing pharmacy news pt update 1110 _3_
For Release December 2010
Blue Cross and Blue Shield of Alabama’s Pharmacy and Therapeutics (P & T) Committee recently approved updates to the Prescription Drug Guide and made clinical program changes to select medications. All information is accessible online at www.bcbsal.com.The P & T Committee consisting of doctors, pharmacists, nurses, and other healthcare professionals advises and makes recommendations based on clinical and cost-effective outcome reviews. Preferred Glucose Meters and Test Strips – Effective January 1, 2011
Effective January 1, 2011, Bayer products (i.e., Ascensia Contour and Breeze 2) will move to a preferred status, along with Roche products (i.e., Accu-Chek). Lifescan products (i.e., One Touch) will move to a non-preferred status, along with all other products in this category. All members who currently use a Lifescan product will receive a letter with instructions on to obtain a preferred meter. Prescription Drug Guide Updates – Effective January 1, 2011 The following drugs may have changes that affect what a member will be required to pay at the time of purchase. All members that are negatively affected by a formulary change that is not a result of a generic being available will receive a letter. BRAND NAME (generic name if available) Description of Change
Move from Tier 2 to Tier 3, generics available
Move from Tier 2 to Tier 3, generics available
Move from Tier 2 to Tier 3, generics available
For a complete listing of generic and preferred brand alternatives, please refer to the Prescription Drug Guide located in the Pharmacy section of the Blue Cross and Blue Shield of Alabama website at the address below:
www.bcbsal.org/pharmacy/index.cfm Clinical Program Updates – Effective January 1, 2011
The following medication dispensing limits (DL), prior authorization (PA), and/or step therapy (ST) programs have been added or revised: New or Revised PA or ST Programs Policy Name Target Drugs Coverage Criteria Changes NEW – ST program requires use of at least one
generic ACEI or ARB prior to use of Preferred Brand
ARBs (Diovan/HCT, Exforge/HCT, Micardis/HCT), and
requires use of at least one Preferred Brand ARB prior
to use of a Non-Preferred Brand ARB or Renin
* Members with a claim for the requested brand ARB or
Renin Inhibitor within the past 90 days will not be
Tekamlo Tekturna/HCT Teveten/HCT Tribenzor Twynsta Valturna
NEW – ST program requires use of at least one
generic Statin prior to use of a branded Statin.
* Members with a claim for the requested brand Statin
within the past 90 days will not be subject to step
REVISED – Members must have a diagnosis of chronic idiopathic constipation or irritable bowel syndrome with constipation with documentation of symptoms for ≥3 months. Members must try at least two alternative laxative treatments prior to coverage of Amitiza. REVISED – Addition of Staxyn to PA/QL program.
Under standard benefits, Staxyn will require PA for
men <50 years of age and will have a QL of 8 tablets
REVISED – PA program will now require use of the
preferred product Pegasys prior to use of non-preferred PegIntron for all new starts.
REVISED – Addition of generic omeprazole-sodium
bicarbonate as target for ST program. ST program will
require use of generic lansoprazole or omeprazole prior
omeprazole-
to use of generic omeprazole-sodium bicarbonate or
sod bicarb
any other target PPI. QL of 1 tablet per day will apply.
pantoprazole Prevacid Prilosec Protonix Zegerid
REVISED – Addition of Epiduo and Veltin to PA
program which under standard benefits requires PA for
Differin Epiduo Retin-A tretinoin Tretin-X Tazorac Veltin Ziana New Dispensing Limits Brand (Generic) Name Strength Dispensing Limit per Month
* If strengths are not specifically listed, quantity limits apply to all available strengths. Note: Coverage is subject to each member’s specific benefits. Group specific policies will supersede these policies when applicable. Please refer to the member’s benefit plans. For complete details, pharmacy policies may be viewed on the Blue Cross and Blue Shield of Alabama website at the address below: www.bcbsal.org/providers/pharmPolicies/final.cfm
Necrotic Enteritis Dr. Bruce Hunter,1 Ashley Whiteman,1 Dr. Babak Sanei,2 and Al Dam2 Necrotic enteritis (NE) s a bacterial disease of the intestinal tract that occurs in a variety of species. It is primarily a disease of commercial broiler chickens, but also occurs in turkeys, and wild and domestic waterfowl. Status in Canada Necrotic enteritis is one of the most significant d
CHLAMYDIAL INFECTIONS 1. Agent : Chlamydia trachomatis . 2. Identification : a. Symptoms : A sexually transmitted primarily as urethritis and in females as 3. Incubation : Poorly defined, probably 7-14 Complications of male urethral infections include epididymitis, and 4. Reservoir : Humans. 5. Source : Genital secretions from infected inflammation and mucopurulent disc